title: [Discrepancies between primary tumor and metastasis: impact on personalized medicine].
abstract: Molecular characterization of tumors is critical for the development and appropriate use of many anti-cancer agents. Potential discrepancies between primary tumor and secondary lesions lead to question on the optimal modalities for evaluation of biomarkers. In light of recent data, the need of iterative biopsies in metastatic setting has been suggested but technical and methodological limits in such analyses should not be ignored and this strategy can not be definitively validated. The evaluation of spatial and temporal variability of biomarkers in solid tumors should take into account tumoral context and therapeutic history of each patient for the development of personalized medicine in oncology.
authors.affiliation: Inserm U981, Institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif Cedex, France. stephane.vignot@psl.aphp.fr
authors.forename: Stéphane
authors.initials: S
authors.lastname: Vignot
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Soria
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D001706:Biopsy; D018450:Disease Progression; D006801:Humans; D009362:Neoplasm Metastasis / Q000473:pathology; D009369:Neoplasms / Q000737:chemistry / Q000473:pathology / Q000628:therapy; D057285:Precision Medicine; D012196:Review Literature as Topic
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor
keywords: discrepancies; metastasis; personalized medicine; primary tumor